JSJohn T. Saxon

John T. Saxon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John T. Saxon has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PASCAL Precision System Outcomes by Implant Location and Lesion Location in Degenerative Mitral Regurgitation Patients From the STS/ACC TVT Registry

    by P. Kasi Ramanathan, Raj Makkar, Thomas Waggoner, Azeem Latib, Robert M. Kipperman, Ivan Hanson, Anjan K. Sinha, Tarun Chakravarty, Rahul P. Sharma, Jeremiah P. Depta, et al.

    Background: Mitral valve transcatheter edge‐to‐edge repair can be more challenging in noncentral regions of the valve and in anterior or bileaflet lesions. We assess effect of implant location and leaflet lesion location on safety and effectiveness of PASCAL Precision system in degenerative mitral regurgitation (MR). Methods: Mitral valve transcatheter edge‐to‐edge repair outcomes in patients with degenerative MR treated with PASCAL Precision system (September 2022–October 2024), from the US STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) Registry, were analyzed by implant location (A2P2/non‐A2P2) and leaflet lesion location (anterior/posterior/bileaflet). Procedural, clinical, and echocardiographic outcomes to 30 days were assessed. Results: At 30 days, both A2P2 (n=1526) and non‐A2P2 (n=299) groups had low event rates (cardiovascular mortality: 1.1% versus 1.0%, mitral valve reintervention: 0.4% versus 0.0% and single leaflet device attachment: 0.5% versus 0.3%; all P >0.05) and demonstrated significant MR reduction ( P 0.05), and demonstrated significant MR reduction ( P P =0.459) (MR ≤2+: 94.1%, 93.1%, and 94.5%; MR ≤1+: 79.0%, 69.2%, and 72.4%). All groups experienced significant improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary scores (∆21.4, ∆18.8, ∆12.0 points; P =0.087). Conclusion: In real‐world patients with degenerative mitral regurgitation, treatment with the PASCAL Precision system was associated with favorable safety and effectiveness at 30 days, regardless of implant location or leaflet lesion location.

  • Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease

    by Evan L. O’KEefe, John T. Saxon, Yoon Joo Cho, Philip G. Jones, Daniel B. Mark, Sripal Bangalore, William E. Boden, Gregg W. Stone, Harmony R. Reynolds, Judith S. Hochman, et al.

    BACKGROUND: Patient-centered prognostic assessment in chronic coronary disease is vital for treatment optimization. Although the Seattle Angina Questionnaire Summary Score (SAQ-SS) correlates with clinical outcomes, clinicians lack guidance on how to weigh prior, current, or changes in scores, and whether prognostic significance varies by revascularization strategy. METHODS: The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches; 2012–2019) was a global, multicenter, randomized controlled trial. This secondary analysis evaluated the prognostic value of serial SAQ-SS assessments. The SAQ-SS ranges from 0 to 100, with higher scores indicating better health status. To simulate routine clinical care, the follow-up in ISCHEMIA was equated to outpatient clinic visits—we defined the 3-month SAQ-SS as the prior score and the 6-month assessment as the current score in the clinic. Analyses were stratified by treatment strategy: conservative management and invasive management with revascularization. Cox proportional hazards models assessed the association of the prior score, the current score, and the change in scores with ISCHEMIA’s primary composite end point (cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, and resuscitated cardiac arrest), adjusting for 17 clinical covariates. RESULTS: This analysis included 3405 participants (1965 in conservative management: 77.4% male, mean age 64.3 years±9.5; 1440 in invasive management: 77.6% male, mean age 64.0 years±9.4). Over a median follow-up of 3.2 years, 215 (11.0%) and 96 (6.7%) participants in the conservative and invasive cohorts, respectively, experienced the primary composite end point. Higher prior, current, and change SAQ-SS were each independently associated with a lower risk of cardiovascular events. In the conservative cohort, each 5-point increase in the current SAQ-SS was associated with a 7% lower risk of the primary end point (hazard ratio, 0.93 [95% CI, 0.90–0.96]); in the invasive cohort, the association was 9% (hazard ratio, 0.91 [95% CI, 0.86–0.96]). CONCLUSIONS: In patients with chronic coronary disease, the most recent SAQ-SS is the strongest health status predictor of future cardiovascular events. Serial SAQ-SS assessments provide a practical, dynamic, and patient-centered approach for updating prognosis in chronic coronary disease management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01471522.

  • Mitral Valve Leaflet Modification

    by James M. McCabe, Robert J. Lederman, David Elison, Greg Condos, Toby Rogers, Amar Krishnaswamy, Frederik Uttenthal, Stephanie Sellers, Prakriti Gaba, Jeremy Rier, et al.


  • UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves

    by Elsa Hebbo, John T. D’ANgelo, Anton Camaj, Anas T. Noman, Hiroki A. Ueyama, Liana T. Alcaro, Roger J. Laham, Gennaro Giustino, Mostafa Naguib, Adnan M. Halboni, et al.


  • Late Evolut Valve Failure

    by John T. Saxon, Chetan Huded

  • Aortic Valve Leaflet Modification

    by Toby Rogers, Rim N. Halaby, Adam B. Greenbaum, Christopher G. Bruce, Vasilis C. Babaliaros, Jaffar M. Khan, Mohamed Abdel-Wahab, Matti Adam, Nicholas S. Amoroso, Ole de Backer, et al.


  • Open Access

    Intra‐Annular Versus Supra‐Annular Self‐Expanding Valves for Valve‐in‐Valve TAVR

    by John T. Saxon, Alex Wisniewski, Ibrahim Sultan, Jeffrey Chidester, Michael Ragosta, Leora Yarboro, Derek Serna‐Gallegos, Kenan Yount, Adanna Akujuo, Jared Beller, et al.

    Background: A limitation of Valve‐in‐Valve (VIV) transcatheter aortic valve replacement (TAVR) is patient‐prosthesis mismatch (PPM), which is associated with worse quality of life and heart failure hospitalizations. As such, strategies to avoid PPM are desired. We compared the clinical and hemodynamic results of VIV TAVR with intra‐annular self‐expanding valves (IA SEV, Navitor, Abbott Vascular) versus supra‐annular self‐expanding valves (SA SEV, Evolut, Medtronic). Aims: To evaluate the hemodynamics and clinical outcomes of self‐expanding valve platforms for VIV TAVR. Methods: Patients were treated at two sites. The primary endpoint was the 30‐day mean transvalvular gradient. Secondary endpoints included 30‐day effective orifice area (EOA); and key clinical events including major vascular complication, coronary obstruction, 30‐day all‐cause mortality, stroke, need for reintervention, and new requirement of permanent pacemaker. A linear effects model was fit to adjust for factors related to PPM including surgical valve true inner dimension (TID), balloon post‐dilation, body surface area, and etiology of surgical valve failure. Results: Consecutive patients who underwent VIV TAVR with IA SEV ( n = 48) and SA SEV ( n = 52) are reported; 42% were women, the mean age was 79.2 ± 6.7 years, and the mean STS Predicted Risk of Mortality was 6.0 ± 4.1%. The mean surgical valve TID was 21.5 ± 1.5 mm. At 30 days, there was no difference in mean transvalvular gradient in IA SEV (10.6 ± 3.6 mmHg) and SA SEV (12.3 ± 6.9, p = 0.44). EOA was slightly larger in IA SEV (1.69 ± 0.6 cm 2 ) than in SA SEV (1.40 ± 0.5 cm 2 , p = 0.04) in the unadjusted analysis. After adjustment, there was no significant effect of IA SEV versus SA SEV ( p = 0.28), surgical valve true inner diameter ( p = 0.79), or balloon post‐dilation ( p = 0.37) on gradient. A subset of IA SEV patients who underwent bioprosthetic valve fracture ( n = 5) experienced no annular injury, valve leaflet injury, or valve dysfunction at 30 days. Conclusions: VIV TAVR using an IA SEV was safe in this case series with no difference in hemodynamics between IA SEV and SA SEV. These findings provide support for prospective evaluations of an IA SEV for VIV TAVR.


  • Adult Congenital Heart Disease Interventions

    by Georges Ephrem, Robert M. Gallagher, John T. Saxon